Status:
COMPLETED
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
Lead Sponsor:
Abbott
Conditions:
Dyslipidemia
Coronary Heart Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily ...
Eligibility Criteria
Inclusion
- Adult male and female subjects who voluntarily sign the informed consent.
- Subject has successfully completed one of the three ABT-335, rosuvastatin, simvastatin and atorvastatin combination therapy studies.
Exclusion
- Subject is using or will use investigational medications, except as approved by Abbott.
- Subject has prematurely discontinued his/her initial therapy one of the prior ABT-335, rosuvastatin, simvastatin and atorvastatin calcium combination therapy studies.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1911 Patients enrolled
Trial Details
Trial ID
NCT00300430
Start Date
September 1 2006
Last Update
July 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Global Medical Information
North Chicago, Illinois, United States, 60064